Since the discovery that immunogenicity of infliximab substantially impacts the efficacy of this biologic drug, therapeutic drug monitoring has attracted great interest among gastroenterologists managing patients with inflammatory bowel disease. In the face of negative randomized controlled trials evaluating proactive therapeutic drug monitoring, enthusiasm for this tool has waned. The expanding therapeutic armamentarium has also resulted in uncertainty on how to apply therapeutic drug monitoring to drug classes beyond TNF antagonists. This webinar offers a brief overview of the available evidence for therapeutic drug monitoring in gastroenterology, an illustration of its current role in clinical practice and an outline of potential future developments.
Jurij Hanžel, UMC Ljubljana, Slovenia
Jurij Hanžel is a gastroenterologist at the University Medical Centre in Ljubljana and assistant professor of medicine at the Faculty of Medicine, University of Ljubljana. He obtained his medical degree at the University of Ljubljana and trained as a gastroenterologist at UMC Ljubljana. In 2020, he completed an advanced fellowship in inflammatory bowel disease at the Amsterdam UMC in the Netherlands. In his PhD thesis, he focused on the pharmacokinetics of newly approved monoclonal antibodies for the treatment of inflammatory bowel disease.
His research focuses on inflammatory bowel disease, including clinical trial design, post-operative Crohn’s disease, and therapeutic drug monitoring.
Lisa Schots, Ghent University Hospital, Belgium
Lisa Schots graduated as medical doctor and started her residency in Dermatology at the Vrije Universiteit Brussel in 2018. In 2019, she joined Prof Lambert’s research team at UZ Gent to complement her medical training with scientific input as a PhD student. She focuses on the implementation of personalized care by studying therapeutic drug monitoring and biomarkers of biologics in psoriasis.